Literature DB >> 29351444

Activated human T lymphocytes inhibit TGFβ-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2.

Shannon H Lacy1, Amali P Epa2, Stephen J Pollock1,3, Collynn F Woeller1, Thomas H Thatcher3,4, Richard P Phipps1,2,3,4, Patricia J Sime1,2,3,4.   

Abstract

In pulmonary fibrosis (PF), fibroblasts and myofibroblasts proliferate and deposit excessive extracellular matrix in the interstitium, impairing normal lung function. Because most forms of PF have a poor prognosis and limited treatment options, PF represents an urgent unmet need for novel, effective therapeutics. Although the role of immune cells in lung fibrosis is unclear, recent studies suggest that T lymphocyte (T cell) activation may be impaired in PF patients. Furthermore, we have previously shown that activated T cells can produce prostaglandins with anti-scarring potential. Here, we test the hypothesis that activated T cells directly inhibit myofibroblast differentiation using a coculture system. Coculture with activated primary blood-derived T cells, from both healthy human donors and PF patients, inhibited transforming growth factor β-induced myofibroblast differentiation in primary human lung fibroblasts isolated from either normal or PF lung tissue. Coculture supernatants contained anti-fibrotic prostaglandins D2 and E2, and the inhibitory effect of coculture on myofibroblast differentiation was largely reversed when prostaglandin production was abrogated either by resting the T cells before coculture or via specific pharmacological inhibitors. Moreover, coculture conditions induced COX-2 in HLFs but not in T cells, suggesting that T cells deliver an activating signal to HLFs, which in turn produce anti-fibrotic prostaglandins. We show for the first time that coculture with activated primary human T lymphocytes strongly inhibits myofibroblast differentiation, revealing a novel cell-to-cell communication network with therapeutic implications for fibrotic lung diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29351444      PMCID: PMC5966783          DOI: 10.1152/ajplung.00565.2016

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  79 in total

1.  Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.

Authors:  Keith C Olsen; Amali P Epa; Ajit A Kulkarni; R Matthew Kottmann; Claire E McCarthy; Gail V Johnson; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

2.  Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines.

Authors:  R Rezzonico; D Burger; J M Dayer
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

3.  A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation.

Authors:  A E Moore; L E Young; D A Dixon
Journal:  Oncogene       Date:  2011-08-08       Impact factor: 9.867

4.  Inhibition of myofibroblast apoptosis by transforming growth factor beta(1).

Authors:  H Y Zhang; S H Phan
Journal:  Am J Respir Cell Mol Biol       Date:  1999-12       Impact factor: 6.914

5.  Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes.

Authors:  Steven E Feldon; Charles W O'loughlin; Denise M Ray; Shira Landskroner-Eiger; Kathryn E Seweryniak; Richard P Phipps
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

6.  Inhibition of human lung fibroblast growth by mononuclear cells.

Authors:  J A Elias; M D Rossman; R P Daniele
Journal:  Am Rev Respir Dis       Date:  1982-06

7.  Human lung fibroblasts produce proresolving peroxisome proliferator-activated receptor-γ ligands in a cyclooxygenase-2-dependent manner.

Authors:  Shannon H Lacy; Collynn F Woeller; Thomas H Thatcher; Krishna Rao Maddipati; Kenneth V Honn; Patricia J Sime; Richard P Phipps
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-09       Impact factor: 5.464

8.  Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung.

Authors:  Steven K Huang; Anne M Scruggs; Richard C McEachin; Eric S White; Marc Peters-Golden
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

9.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Inhibition of collagen synthesis by mononuclear cell supernates.

Authors:  S A Jimenez; W McArthur; J Rosenbloom
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

View more
  5 in total

1.  Prostaglandin E2 inhibits profibrotic function of human pulmonary fibroblasts by disrupting Ca2+ signaling.

Authors:  Subhendu Mukherjee; Wei Sheng; Alexander Michkov; Krishna Sriarm; Rui Sun; Anna Dvorkin-Gheva; Paul A Insel; Luke J Janssen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-02-13       Impact factor: 5.464

Review 2.  Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).

Authors:  Paolo Spagnolo; Oliver Distler; Christopher J Ryerson; Argyris Tzouvelekis; Joyce S Lee; Francesco Bonella; Demosthenes Bouros; Anna-Maria Hoffmann-Vold; Bruno Crestani; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2020-10-09       Impact factor: 19.103

3.  Catalpol Protects Against Pulmonary Fibrosis Through Inhibiting TGF-β1/Smad3 and Wnt/β-Catenin Signaling Pathways.

Authors:  Fan Yang; Zhen-Feng Hou; Hao-Yue Zhu; Xiao-Xuan Chen; Wan-Yang Li; Ren-Shuang Cao; Yu-Xuan Li; Ru Chen; Wei Zhang
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

Review 4.  Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis.

Authors:  Olivier Burgy; Sabrina Loriod; Guillaume Beltramo; Philippe Bonniaud
Journal:  Cells       Date:  2022-04-03       Impact factor: 6.600

Review 5.  The Roles of Various Prostaglandins in Fibrosis: A Review.

Authors:  Ke Li; Jing Zhao; Mingxuan Wang; Lingzhi Niu; Yuanping Wang; Yanxia Li; Yajuan Zheng
Journal:  Biomolecules       Date:  2021-05-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.